ER

Drug discovery services market to reach $16.6B in 2015

Monday, December 10, 2012 10:09 AM

A new report by visiongain, an independent media company based in London, predicts that the world market for drug discovery outsourcing will reach $16.6 billion in 2015. That revenue forecast and others appear in “DrugDiscovery Outsourcing: World Market 2013-2023,” published in November 2012.

More... »

DIA begins transition to new executive leadership

Monday, December 10, 2012 09:12 AM

DIA, a neutral, global, nonprofit association that provides knowledge resources across the full spectrum of medical product development, announced that Paul Pomerantz, worldwide executive director of DIA, will be leaving effective March 3, 2013, to assume the position of CEO for the American Society of Anesthesiologists.

More... »

NanoString touts positive results from study of PAM50-based breast cancer assay

Friday, December 7, 2012 03:01 PM

NanoString Technologies, a Seattle, Wash.-based privately held provider of life science tools for translational research and developer of molecular diagnostic products, released positive results from the second clinical validation study of its in vitro diagnostic breast cancer assay based on the PAM50 gene expression signature.

More... »

UT MD Anderson, GSK collaborate on new approach to cancer immune therapy

Friday, December 7, 2012 02:06 PM

The University of Texas MD Anderson Cancer Center and global healthcare company GlaxoSmithKline (GSK) have signed a research collaboration and license agreement to develop new therapeutic antibodies that promote an immune system attack against cancer.

More... »

Former Merck Serono headquarters in Geneva could host a new Wyss Institute

Friday, December 7, 2012 01:43 PM

A dedicated consortium comprised of the École Polytechnique Fédérale de Lausanne (EPFL), the University of Geneva (UNIGE), Dr. Hansjörg Wyss and the Bertarelli family has developed a project to convert part of the former Merck Serono site in Geneva, Switzerland, into a multi-development facility.

More... »

Prize4Life launches PRO-ACT, largest ALS trials database ever created

Friday, December 7, 2012 10:42 AM

Prize4Life, a nonprofit organization dedicated to accelerating discovery of treatments and a cure for ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig's disease), launched the PRO-ACT (Pooled Resource Open-Access ALS Clinical Trials) database, the largest ALS clinical trial database ever created.

More... »

CoreLab enters early Alzheimer's imaging market space

Friday, December 7, 2012 10:19 AM

CoreLab Partners, an independent core lab providing centralized cardiac safety services and medical imaging assessment, has launched new imaging capabilities targeted at the utilization of independent central image review in the detection of early Alzheimer’s disease.

More... »

UAE, Merck Serono, Neopharma form first pharmaceutical production agreement

Wednesday, December 5, 2012 11:35 AM

Merck Serono, a division of Germany-based Merck, and a local manufacturer, Neopharma, have formed the first partnership of its kind to locally produce Merck branded medication in the UAE for distribution across the Middle East.

More... »

Geron discontinues GRN100, cuts 43 workers

Wednesday, December 5, 2012 11:08 AM

Geron, a Menlo Park, Calif.-based biopharmaceutical company developing first-in-class therapies for cancer, has discontinued development of GRN1005, its peptide-drug conjugate designed to treat cancers in the brain. Going forward, the company will focus on the development of imetelstat, its telomerase inhibitor, in hematologic myeloid malignancies and in patients with solid tumors that have short telomeres.

More... »

AAIPharma appoints Browne as director of analytical chemistry

Wednesday, December 5, 2012 11:02 AM

AAIPharma Services, a provider of pharmaceutical product development services, has appointed David Browne as the company's director of analytical chemistry for its Edison, N.J., laboratory.

More... »